NASDAQ · RDNT
Healthcare · Medical - Diagnostics & Research
$73.54
Up+$0.61 (+0.83%)
Updated Oct 29, 2026, 2:52 PM
SID Score
5.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance · RDNT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 28, 2026
RDNT closed at $73.54 after 21 trading sessions, up 6.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 28, 2026 | $73.48 | $75.02 | $73.33 | $73.54 | 633.16K |
| Oct 27, 2026 | $70.53 | $74.56 | $70.49 | $73.54 | 1.27M |
| Oct 26, 2026 | $70.58 | $71.77 | $69.76 | $70.05 | 340.09K |
| Oct 23, 2026 | $69.53 | $71.00 | $69.43 | $70.34 | 403.64K |
| Oct 22, 2026 | $67.77 | $70.39 | $67.60 | $70.26 | 318.37K |
| Oct 21, 2026 | $69.48 | $70.26 | $68.055 | $68.41 | 458.55K |
| Oct 20, 2026 | $69.92 | $71.06 | $69.03 | $69.65 | 326.24K |
| Oct 19, 2026 | $68.91 | $70.00 | $68.25 | $69.27 | 342K |
| Oct 16, 2026 | $70.41 | $70.49 | $68.51 | $68.80 | 385.9K |
| Oct 15, 2026 | $70.12 | $70.82 | $69.07 | $70.41 | 461.23K |
| Oct 14, 2026 | $70.65 | $71.90 | $69.02 | $69.16 | 477.92K |
| Oct 13, 2026 | $70.81 | $72.15 | $70.0025 | $71.51 | 478.05K |
| Oct 12, 2026 | $70.88 | $71.78 | $70.11 | $71.49 | 383.36K |
| Oct 9, 2026 | $68.41 | $71.105 | $68.13 | $70.91 | 507.44K |
| Oct 8, 2026 | $68.16 | $68.50 | $66.23 | $68.21 | 722.26K |
| Oct 7, 2026 | $69.57 | $70.66 | $68.45 | $68.61 | 398.63K |
| Oct 6, 2026 | $71.27 | $71.545 | $69.44 | $70.28 | 291.72K |
| Oct 5, 2026 | $69.87 | $71.86 | $69.40 | $70.57 | 681.37K |
| Oct 2, 2026 | $68.52 | $70.675 | $67.80 | $69.93 | 574.2K |
| Oct 1, 2026 | $68.80 | $69.70 | $67.32 | $67.70 | 928.74K |
| Sep 30, 2026 | $70.22 | $70.85 | $68.94 | $68.94 | 621.24K |
The latest Smart Investors Daily articles mentioning RDNT.
Company
Market Activity
Research & News
RDNT research
Company profile and research snapshot.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2026 | Barclays | Overweight | — |
| Aug 11, 2026 | Truist Securities | Buy | — |
| May 20, 2026 | Barclays | Overweight | — |
| Apr 21, 2026 | Barclays | Overweight | — |
| Jan 9, 2026 | Keybanc | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 22, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Yahoo · Oct 17, 2026
RadNet recently reported quarterly revenue of $622.7 million, up 25% year on year, with earnings ahead of analyst estimates and performance that exceeded consensus expectations. The update reinforced how RadNet’s mix of imaging centers and digital health services is benefiting from steady diagnostic demand and the growing use of AI-driven tools in clinical workflows. We will now look at how RadNet's strong revenue beat and earnings surprise could influence the existing investment narrative...
Benzinga · Oct 13, 2026
RadNet (NASDAQ:RDNT) has outperformed the market over the past 15 years by 12.77% on an annualized basis producing an average annual return of 25.97%. Currently, RadNet has a market capitalization of $5.63 billion.
Yahoo · Oct 8, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how testing & diagnostics services stocks fared in Q2, starting with RadNet (NASDAQ:RDNT).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RDNT.
